HK1226065A1 - 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法 - Google Patents

連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法

Info

Publication number
HK1226065A1
HK1226065A1 HK16114377A HK16114377A HK1226065A1 HK 1226065 A1 HK1226065 A1 HK 1226065A1 HK 16114377 A HK16114377 A HK 16114377A HK 16114377 A HK16114377 A HK 16114377A HK 1226065 A1 HK1226065 A1 HK 1226065A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
compositions
methods
associated kinase
adapter associated
Prior art date
Application number
HK16114377A
Other languages
English (en)
Inventor
Bi Yingzhi
Kumi Godwin
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of HK1226065A1 publication Critical patent/HK1226065A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK16114377A 2014-03-17 2016-12-16 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法 HK1226065A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461953976P 2014-03-17 2014-03-17

Publications (1)

Publication Number Publication Date
HK1226065A1 true HK1226065A1 (zh) 2017-09-22

Family

ID=52727478

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114377A HK1226065A1 (zh) 2014-03-17 2016-12-16 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法

Country Status (15)

Country Link
US (1) US9682982B2 (zh)
EP (2) EP3119783B1 (zh)
JP (1) JP6553081B2 (zh)
CN (1) CN106103447B (zh)
AR (1) AR099766A1 (zh)
AU (1) AU2015231672B2 (zh)
CA (1) CA2941870C (zh)
DK (2) DK3719021T3 (zh)
ES (2) ES2821441T3 (zh)
HK (1) HK1226065A1 (zh)
HU (1) HUE050975T2 (zh)
PL (2) PL3119783T3 (zh)
PT (2) PT3119783T (zh)
TW (1) TW201620911A (zh)
WO (1) WO2015142714A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2834243T (pt) * 2012-03-09 2018-08-01 Lexicon Pharmaceuticals Inc Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização
JP6473146B2 (ja) 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピロロトリアジンキナーゼ阻害剤
CN109369576B (zh) * 2018-09-19 2020-11-27 上海凌凯医药科技有限公司 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法
JP2023522689A (ja) * 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ＣｏＶ－２２９Ｅ又はＣｏＶ－ＯＣ４３コロナウイルス感染症の治療において使用される４－（３－（ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－５－イル）ピペラジン
CA3175970A1 (en) 2020-04-21 2021-10-28 Suma GOPINATHAN Aak1 inhibitors for use in treating viral infections
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2417138B1 (en) * 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2013134336A2 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
PT2834243T (pt) 2012-03-09 2018-08-01 Lexicon Pharmaceuticals Inc Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização
CA2866164C (en) * 2012-03-09 2020-07-07 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof

Also Published As

Publication number Publication date
ES2821441T3 (es) 2021-04-26
EP3719021B1 (en) 2022-03-09
PT3119783T (pt) 2020-09-24
EP3719021A1 (en) 2020-10-07
JP2017507980A (ja) 2017-03-23
WO2015142714A1 (en) 2015-09-24
PL3119783T3 (pl) 2021-01-11
DK3119783T3 (da) 2020-09-28
EP3119783B1 (en) 2020-06-24
DK3719021T3 (da) 2022-06-13
TW201620911A (zh) 2016-06-16
EP3119783A1 (en) 2017-01-25
CA2941870C (en) 2022-07-19
AR099766A1 (es) 2016-08-17
US20160039824A1 (en) 2016-02-11
JP6553081B2 (ja) 2019-07-31
AU2015231672A1 (en) 2016-09-15
CN106103447B (zh) 2019-07-16
PT3719021T (pt) 2022-04-08
US9682982B2 (en) 2017-06-20
AU2015231672B2 (en) 2019-06-20
CA2941870A1 (en) 2015-09-24
CN106103447A (zh) 2016-11-09
PL3719021T3 (pl) 2022-06-20
HUE050975T2 (hu) 2021-01-28
ES2911388T3 (es) 2022-05-19

Similar Documents

Publication Publication Date Title
RS59139B1 (sr) Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
ZA201700786B (en) Protein kinase c inhibitors and methods of their use
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
HK1258996A1 (zh) 新型fyn激酶抑制劑的方法、組合物以及用途
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
HK1226065A1 (zh) 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法
EP3190886A4 (en) Compositions and methods of use thereof
AP2016009489A0 (en) Oligonucleotide compositions and methods of making the same
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HK1243404A1 (zh) 色酰胺組合物和使用方法
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
IL261794A (en) Preparations and methods for using them
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
HK1249039A1 (zh) 用於體重控制的基於植物的組合物和使用方法
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors
AU2014905067A0 (en) Compositions and methods of use
AU2014902829A0 (en) Compositions and Methods of Use